Written Question: Risks posed by the AstraZeneca vaccine

(Source: European Parliament)

Date submitted: 26 March 2021

Question for written answer E-001703/2021
to the Commission
Rule 138
César Luena (S&D)

Subject: Risks posed by the AstraZeneca vaccine

The temporary suspension by a number of Member States of the use of the AstraZeneca shot in their vaccination campaigns owing to the risk of blood clots and the company’s failure to meet its delivery schedule is making it harder for the EU to achieve its vaccination targets.

The European Medicines Agency (EMA) has not yet been able to exclude the causal link between the AstraZeneca vaccine and a particular type of blood clot that could be associated with pre-existing conditions.

  1. If delivery delays persist and if the EMA establishes that there is a risk of blood clots occurring in those with certain pre-existing conditions, will the Commission work with the WHO to improve vaccine mixes so that second doses of one of the other vaccines can be given?
  2. With regard to new variants, the Commission recommends that Member States genetically sequence at least 5% of COVID cases but some Member States have little or no capacity to analyse the genomic sequencing of the virus. What support could the Commission give Member States to help them to identify variants?
%d bloggers like this: